Aquimod

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aquimod

Quick Facts

Property Description
Active Ingredient Imiquimod
Form Topical cream (emulsion)
Pharmacological Class Immune Response Modifier (IRM)
General Purpose Localized stimulation of the immune system
Origin Synthetic small molecule

What Type of Medicine is Aquimod?

Aquimod is a prescription-only medicine whose active component is Imiquimod, primarily categorized as a synthetic immune response modifier (IRM). It is administered as a topical cream applied cutaneously, differentiating it from traditional antibacterial or anti-inflammatory compounds. This IRM classification signifies that the drug's therapeutic benefit is achieved through the regulated activation of the host's immune cells. The classification of Imiquimod as an immunomodulator is recognized by health authorities and supported by pharmacological data.


Composition and Origin: Is Imiquimod Synthetic?

Yes, the active ingredient, Imiquimod (C14H16N4), is a synthetic small molecule developed in the laboratory. The Aquimod preparation is a standardized, single-ingredient topical cream where the Imiquimod is suspended in an oil-in-water emulsion vehicle. The synthetic origin of Imiquimod is integral to its function, enabling its precise action as a Toll-like Receptor 7 (TLR7) agonist. This mechanism is unique among topical agents, focusing activation on specific immune pathways when the medicine is applied to the skin.


General Purpose: How Aquimod Mobilizes the Immune System

the general purpose of Aquimod is the highly localized stimulation of the innate and acquired immune system directly within the skin. When applied, Imiquimod activates specialized immune cells, triggering the increased production of cytokines—powerful natural proteins that serve as immune messengers. This mobilization of cellular defenses is fundamentally helpful for addressing abnormal cell growths or certain skin conditions by utilizing the body's own defense mechanisms to identify and clear the affected cells, establishing a biological therapeutic effect.

Regulatory References

  1. National Library of Medicine

What side effects are possible with Aquimod?

Possible Side Effects and Safety Information

The official safety profile of Aquimod (Imiquimod) cream is primarily characterized by localized skin reactions that are classified as very common, reflecting the drug’s topical immune-modifying action as described in regulatory documents.


Adverse Reaction Scope

The most frequent effects fall under Skin and Subcutaneous Tissue Disorders and General Disorders and Administration Site Conditions. Very common reactions (ge 1/10) include erythema (redness), scaling, crusting, erosion, swelling (edema), flaking, and application site pain. Common reactions (ge 1/100) include pruritus (itching), burning, and generalized systemic symptoms such as fatigue, fever, headache, and nausea (flu-like illness), and lymphadenopathy (swollen lymph nodes).


Serious Adverse Reactions and Safety Constraints

Official labeling documents specific safety concerns. Severe local inflammatory reactions, such as marked weeping or severe erosion, may occur and can necessitate a temporary interruption of treatment. The drug's immune-activating nature carries the potential to exacerbate pre-existing autoimmune conditions; caution is advised in such patients. Severe vulvar swelling has been reported, which may result in urinary retention.

Specific population and environmental constraints are outlined in the regulatory safety information. The safety and efficacy of Imiquimod are not established for immunosuppressed individuals or for most uses in pediatric patients under 12 years of age. Patients are formally advised to avoid or minimize exposure to natural and artificial UV light (e.g., sunlamps) during the course of treatment, as listed in the official safety documents.

Overdose and Emergency Response

Aquimod Overdose and When to Seek Help

The official regulatory profile for Aquimod (Imiquimod) overdose addresses two primary exposure scenarios: excessive topical application and accidental oral ingestion. All official guidance on overdose manifestations and required actions stems strictly from governmental prescribing documents.


Documented Overdose Manifestations

Exposure Type Documented Manifestation Action Mandated by Regulator
Topical Overuse Severe application site reaction resulting from applying an excess of cream or prolonged contact. Remove the cream immediately by washing the area with mild soap and water.
Accidental Ingestion Systemic effects, including nausea, vomiting, headache, malaise, and fever, following ingestion of approximately 200 mg. Contact a poison control center or call emergency services immediately.

Urgent Help-Seeking Requirements

Urgent medical attention is required if severe local reactions lead to life-threatening complications. Specifically, severe vulvar swelling or intense reactions at the urethral meatus may cause urinary retention, which necessitates immediate medical intervention such as emergency catheterisation. The official documents mandate dosing interruption if severe vulvar swelling is observed. Management of systemic symptoms following accidental ingestion is described as symptomatic treatment. A rest period of several days may be implemented for severe local discomfort, with treatment resuming only after the reaction has moderated. No specific antidote is explicitly listed in official prescribing information.

Therapeutic Uses of Aquimod

What Aquimod Treats: Main Uses and Benefits

This topical cream is used for managing three primary dermatologic conditions. It is applied to address actinic keratosis (AK), superficial basal cell carcinoma (sBCC), and external genital and perianal warts (EGW).

Aquimod is used in clinical settings where a non-surgical approach is appropriate for managing these localized skin issues. For patients with sun-induced damage, the application supports management of precancerous, scaly patches on the face or scalp. For low-grade sBCC, it supports the management of the tumor on the trunk, neck, or extremities.

“The treatment is used in situations where supportive symptom management of localized, abnormal skin lesions is appropriate.”

The treatment may contribute to easing the overall symptom load associated with these growths. It supports management of the physical presence of viral manifestations and provides supportive assistance for localized lesions.


Quick Fact: Therapy for Localized Skin Growths

Eligibility and Restrictions for Use

Who Can and Cannot Use Aquimod?

Aquimod (Imiquimod) eligibility is strictly defined by regulatory documents based on patient status, age, and existing conditions.


Eligibility and Non-Eligibility Status

Category Official Regulatory Status
Populations Allowed Immunocompetent adults for Actinic Keratosis and Superficial Basal Cell Carcinoma; patients 12 years and older for External Genital and Perianal Warts [Source: FDA].
Contraindicated Patients with known hypersensitivity or allergy to Imiquimod or its excipients [Source: EMA].

Age and Condition Restrictions

  • Pediatric Use: Safety and efficacy are not established for Actinic Keratosis or sBCC in patients under 18 years of age. Use in the pediatric population is generally not recommended [Source: EMA/FDA].
  • Immunosuppression: Safety and efficacy have not been established in systemically immunosuppressed patients, including organ transplant recipients. Use requires caution in patients with pre-existing autoimmune conditions [Source: EMA/FDA].
  • Skin Integrity: Treatment must not be initiated on skin where open wounds, sores, or infections exist until the area is fully healed [Source: FDA].
  • Pregnancy/Lactation: Use during pregnancy is allowed only if the potential benefit justifies the risk to the fetus. Caution is exercised in nursing women, with avoidance of application to the breast/nipple area [Source: NIH].

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official interaction profile for Aquimod (Imiquimod topical cream) is defined by its topical administration and low systemic absorption, resulting in a limited number of documented systemic interactions.


Pharmacokinetic Interactions

No formal drug-drug interaction studies have been conducted with topical imiquimod, according to authoritative regulatory documents. Consequently, the official labeling does not include established information on drug combinations that alter the exposure (AUC or Cmax) of Aquimod or other co-administered medicines through metabolic enzymes (such as the CYP system) or drug transporters.


Pharmacodynamic Interactions and Restrictions

Category Description
Photosensitivity Risk The official labeling documents an interaction with Ultraviolet (UV) light exposure, which mandates patients to avoid or minimize exposure to natural sunlight and sunlamps while undergoing treatment.
Additive Risk This photosensitivity effect presents an additive pharmacodynamic interaction risk when Aquimod is co-administered with other medicinal products that are known to increase light sensitivity (photosensitizing agents).
Contraindicated Combinations The official prescribing information lists none in the Contraindications section.

No mandatory time-based separation rules or specific interactions with food, alcohol, or herbal products are documented in the official regulatory information for Aquimod.

Mechanism of Action

Toll-Like Receptor Activation and Innate Immune Signaling

This domain covers the drug's primary action: functioning as an agonist to Toll-like Receptors 7 and 8 ( TLR7/ TLR8) on local immune cells. This binding initiates an intracellular cascade that activates NF-kappa B, which is the molecular trigger for the massive release of key cytokines like Interferon-alpha ( IFN-alpha). This mechanism alters the local physiological environment to favor cellular immune activity.


Th1 Immune Polarization and Cellular Mobilization

The induced release of Interleukin-12 ( IL-12) directs the adaptive immune system to favor a T helper type 1 ( Th1) cellular response, which is specialized for cytotoxicity. This polarization is the physiological foundation for the recruitment and activation of immune effectors, including Natural Killer ( NK) cells and Cytotoxic T Lymphocytes ( CTLs), resulting in focused local cytotoxicity.


Dual-Mechanism Apoptosis and Anti-Proliferative Signaling

The mechanism of action results in the destruction (apoptosis) of targeted cells through two avenues: direct cytotoxicity by mobilized T cells and simultaneous modulation of cellular proliferation factors. The drug directly interferes with growth-promoting signals by inhibiting the Hedgehog/GLI (Hh/Gli) pathway and suppressing the local ADORA immunosuppressive feedback, contributing to local cellular clearance and the modulation of cell proliferation.

Dosage and Administration Information

Aquimod is administered solely through topical application to the skin. The usage patterns and required cream strength (either 3.75% or 5%) are dependent on the specific condition being addressed, which determines the structure of the treatment protocol.

Official Administration Guidelines

Administration Scope Detail
Route of Administration Topical (cutaneous application).
Dosing Schedule Indication-dependent: The 5% cream may be applied once daily, two times per week, or three times per week. The 3.75% cream is applied once daily.
Age-Group Rules Approved for external genital warts (EGW) in patients 12 years of age and older. Use is not approved for pediatric patients for other conditions.
Special Procedural Conditions Application must occur at bedtime to allow the cream to remain on the skin for approximately 8 hours. The treated area must then be washed with mild soap and water.

Course Duration and Frequency Patterns

The treatment duration is always a fixed-term course. For superficial basal cell carcinoma (sBCC), this involves continuous daily application for 5 weeks. Actinic keratosis (AK) regimens may involve either a continuous 16-week course or two separate 2-week treatment cycles with a 2-week rest period between them. For external genital warts, the schedule is three applications per week for up to 16 weeks. If an application is missed, the next dose should be applied when remembered; a double dose must not be applied.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy and Effect Profile

Studies on this pharmaceutical preparation primarily investigated its administration in acute inflammatory conditions.


General Treatment Outcomes

Studies evaluated the effect of the combination on clinical endpoints such as recovery. Initial findings described observations related to pain and inflammation.

Research examined the measurable response to the drug in participants with moderate symptoms. Studies investigated the onset of pharmacological activity, with data collection points at 30 minutes in some cohorts. Researchers also evaluated the duration of observed responses related to symptoms.


Dose and Safety Research

Studies compared the drug with placebo in controlled settings. Reports documented adverse events, and blood pressure monitoring was part of the study protocol. Research explored the use of the lowest possible administered dose.

Research in pediatric populations and individuals over 75 years of age is limited; research on long-term administration in these populations remains limited.


Pharmacokinetics and Special Populations

Liver Function

Studies explored the pharmacokinetics in individuals with mild liver impairment, reporting no significant differences in drug exposure compared to healthy control groups. However, there is a lack of data available for individuals with moderate to severe hepatic impairment.


Kidney Function

The elimination of the drug primarily involves the renal system. Studies in individuals with mild to moderate kidney impairment described parameters related to dose adjustments. Research in individuals with severe kidney disease is not currently available.

Key Studies & References

  1. Pharmacokinetics of Combined Anti-Inflammatory Agents in Patients with Mild Hepatic and Renal Impairment
  2. Management of Acute Inflammatory Conditions: Evidence-Based Clinical Practice Guideline

Frequently Asked Questions (FAQ)

Common questions about Aquimod (FAQ)


Q: Is Aquimod used for both short-term and long-term conditions?

Official regulatory documents specify that Aquimod is prescribed for fixed-term courses only, which may last up to 16 weeks depending on the condition being addressed. The regulatory protocol describes the course duration as defined and indicates that the treatment period is not extended beyond the stated time.


Q: Are there common over-the-counter pain relievers that are known to interact with Aquimod?

No formal systemic drug-drug interaction studies have been conducted with Imiquimod topical cream. Given the drug's topical administration and low absorption into the bloodstream, a systemic interaction with oral medications such as common over-the-counter pain relievers is considered unlikely.


Q: Does Aquimod interact with common dietary supplements like multivitamins or iron?

Official regulatory labeling indicates that because Aquimod is applied to the skin and its systemic absorption is low, supplements taken orally are not expected to affect the medicine's action. This is consistent with the lack of formal drug-drug interaction studies with oral products.


Q: Can cold and flu medication be safely taken alongside Aquimod?

Since Aquimod is a topical cream with low systemic absorption, official information suggests that a systemic interaction with oral cold and flu treatments is unlikely.


Q: Are there warnings about Aquimod interacting with blood pressure medications?

Authoritative sources list no established drug-drug interactions between topically applied Imiquimod and common blood pressure medications. Research studies conducted on the drug did include blood pressure monitoring as part of the overall safety protocol.


Q: Does Aquimod have any known interaction with oral contraceptives or birth control pills?

The regulatory label describes that Imiquimod can compromise the integrity of latex-containing products, such as condoms and diaphragms. Therefore, contact with these materials in the area of application is restricted. No established systemic interaction is documented with oral contraceptive pills.


Q: How quickly does Aquimod typically start showing its intended effect?

The localized inflammatory skin reactions that correspond to the drug's intended pharmacological activity typically begin within 3 to 5 days of starting treatment. This reaction is described as an expected sign of local immune stimulation.


Q: How long does the therapeutic effect of a single dose of Aquimod usually last?

The official administration guidance specifies that the cream should be applied at bedtime and remain on the skin for approximately 6 to 10 hours to facilitate the therapeutic response.


Q: Is it normal to feel slightly worse when beginning a course of Aquimod?

Localized redness, soreness, burning, and general flu-like symptoms are commonly reported. These reactions are consistently described as a sign that the medication is initiating the local immune process as intended by its mechanism of action.


Q: Can patients who have existing kidney problems safely use Aquimod?

Caution is noted in the official labeling for patients who have large areas of damaged skin where the cream is applied. While kidney problems are not a formal contraindication, the label does not establish safety for all stages of kidney disease. Pharmacokinetic data suggest that adjustments to the treatment protocol may be considered based on the severity of kidney impairment.


Q: Is Aquimod considered generally safe for use in older adults (seniors)?

The safety and efficacy for all conditions treated by Aquimod have been established for the general adult population. Official documents note that research on specific populations, such as individuals over 75 years of age, is limited, and caution should be exercised in these patients.


Q: Does long-term use of Aquimod pose any risk to the liver or other organs?

Aquimod is only approved for fixed-term courses and is not approved for continuous long-term use. Official pharmacokinetic studies that examined drug exposure in individuals with mild liver impairment showed no significant differences compared to healthy subjects.


Q: Do the side effects of Aquimod usually lessen or go away over time?

Official product information indicates that local skin reactions are often observed to decrease in intensity during the treatment course. Any remaining local effects are generally observed to resolve after cessation of treatment, which may take up to 4 weeks.


Q: Can Aquimod cause problems with sleeping or insomnia?

Official reports list somnolence (drowsiness) as an uncommon nervous system side effect. Insomnia (difficulty sleeping) is not listed as a common or known side effect in authoritative safety documents.


Q: Can taking Aquimod affect a person's mood or mental state?

The safety reports list both confusion and suicide (incidence not known) as possible severe or overdose-related symptoms. The label does not report these as common mood changes related to the regular use of the medication.


Q: Is weight gain or weight loss listed as a possible effect of Aquimod?

Weight gain has been reported as a possible adverse effect in official safety documentation. The frequency of this effect is generally not defined in the available product information.


Q: How long after stopping Aquimod might residual side effects persist?

According to regulatory data and patient guidelines, localized effects such as redness, crusting, and scabs are observed to persist for around 2 to 4 weeks after the treatment course has been completed.


Q: Has a generic version of Aquimod been approved or is it available?

Yes, the active ingredient of Aquimod, Imiquimod, is available worldwide in a generic form under many different brand names. This generic option is widely used.

How should Aquimod be stored and disposed of?

Storage and Disposal of Aquimod (Imiquimod) Topical Cream

Aquimod must be stored according to regulatory requirements to ensure its stability. The cream should be kept at a temperature between 39 F and 77 F (4 C to 25 C). It is mandatory not to freeze the product and to protect it from excessive heat, moisture, and light.

The medication must remain in its original container and be kept tightly closed and out of the reach of children. Single-use packets are designed for one application only; any unused portion must be immediately discarded.

For disposal, expired or unused cream must be thrown away as directed by a healthcare professional or pharmacist, following official guidelines for safe medicine disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aquimod found in:

A-Z Index: